Gilead Sciences’ Indian patent request for hepatitis C drug sofosbuvir faces opposition
US group seeks block on blockbuster Hep-C drug patent in India
I-MAK challenges Gilead sofosbuvir patent in India
I-MAK Opposes Patent Application on Hepatitis C Drug Sofosbuvir
Gilead Sofosbuvir Patent Meets Resistance in India
Advocates Try To Block Gilead Patent For Hep C Drug In India
Low-Cost Drugs in Poor Nations Get a Lift in Indian Court (New York Times)
Indian court ruling hailed as victory for generic drugs (Los Angeles Times)
The Op-Ed: India Deals A Blow to Pharma’s Life Cycle Strategy (Pharmalot)
US business groups say verdict to impact pharma innovation in India (Business Standard)